Related Experiment Video

Updated: Aug 8, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Neuroendocrine Tumor Therapy Response Assessment

Vetri Sudar Jayaprakasam1, Lisa Bodei1

  • 1Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

PET Clinics
|March 1, 2023
PubMed

Insights

Peptide receptor radionuclide therapy is key for neuroendocrine neoplasms (NENs). This review covers biomarkers for assessing treatment response, highlighting challenges and strengths for better patient management.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmacology

Background:

  • Peptide receptor radionuclide therapy (PRRT) is integral to managing neuroendocrine neoplasms (NENs).
  • Gallium-68- and Lutetium-177-labeled somatostatin receptor analogues are now standard, replacing older tracers.
  • Emerging targeted therapies require precise response evaluation.

Purpose of the Study:

  • To provide an overview of biomarkers for assessing treatment response in NENs.
  • To discuss the strengths and weaknesses of current response assessment biomarkers.
  • To address the challenges in evaluating PRRT and targeted therapy efficacy in NENs.

Main Methods:

  • Literature review of PRRT and targeted therapies for NENs.
  • Analysis of biomarker utility in response assessment.
  • Discussion of NEN characteristics influencing response patterns.

Main Results:

  • PRRT with Ga-68 and Lu-177 analogues is a primary treatment modality.
  • Accurate response assessment is crucial but challenging due to NEN heterogeneity.
  • Various biomarkers exist, each with distinct advantages and limitations.

Conclusions:

  • Effective management of NENs relies on accurate response assessment to PRRT and targeted therapies.
  • Understanding biomarker characteristics is essential for clinical decision-making.
  • Further research may refine response evaluation in NENs.
Keywords:
DOTA-Tyr(3)-octreotateNETestNeuroendocrine neoplasmsPPQPeptide receptor radionucleotide therapiesResponse

More Related Videos

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.3K
Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging11:09

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

Published on: July 13, 2010

39.5K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
611